Ajanta Pharma In-licenses Biocon's Semaglutide for 26 Countries

Ajanta Pharma Ltd. has entered into an in-licensing agreement with Biocon Ltd. for the marketing of Semaglutide, a GLP-1 receptor agonist, in 23 countries and semi-exclusive marketing in 3 countries across Africa, the Middle East and Central Asia. The product patent expires in most of these markets in March 2026. Ajanta plans to commercialize the products after receiving regulatory approvals, expected in late 2026 or early 2027. Ajanta Pharma is known for its strong branded generic business with its own field force in over 30 countries across Africa, South-East Asia, Central Asia and the Middle East. It has a robust product pipeline under regulatory approval, which is expected to further strengthen its leadership across key therapeutic segments.